Project Grant F31DA063348

Award Date 10/14/25
Completion Date 5/15/28
Dollars Obligated $85K
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Colorado, USA
Similar Awards
The National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $1,188,822 Project Grant (R01DA059455) to the Icahn School of Medicine at Mount Sinai. The grant will fund a 5-year research project to molecularly and cellularly profile the habenulo-interpeduncular circuit in opioid tolerance and withdrawal. The project aims to examine gene expression and neuronal calcium dynamics in the interpeduncular nucleus during chronic...
This federal Project Grant award for $340,000 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund research to better understand the role of the locus coeruleus-noradrenergic (LC-NE) system in fentanyl withdrawal-induced negative affect behaviors. The research aims to determine whether a newly identified midbrain glutamatergic input to the LC contributes to the negative affective behaviors associated with opioid withdrawal....
This Project Grant award of $847,000 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to evaluate the therapeutic potential of neuropeptide S receptor 1 (NPSR1) agonism for reducing opioid self-administration and relapse in preclinical animal models. The research team at the University of Tennessee Health Science Center will leverage pharmacological tools to investigate NPSR1 as a novel target for treating...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund research to investigate the role of cholinergic interneurons in the ventral tegmental area on opioid-related behaviors. The $373,181 grant, awarded on July 15, 2024 with a completion date of June 30, 2027, aims to determine whether mu-opioid receptors on cholinergic interneurons contribute to opioid reward, consumption, and withdrawal, and how...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $562,014 to the University of California, San Diego (UCSD) for a project titled "Opioid Actions on the Habenulo-Peduncular Circuit". The project aims to investigate the role of the medial habenula and interpeduncular nucleus in mediating the aversive qualities of opioid dependence and withdrawal, using a combination of molecular,...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,076,036 to the University of Pittsburgh to conduct research on targeting prefrontal cortex (PFC) interneurons for personalized treatments in opioid use disorder (OUD). The key objectives are to: Assess how individual differences in PFC theta power and interneuron physiology correlate with fentanyl self-administration and affective disturbances...
This Project Grant award of $159,615 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research to predict craving and relapse in opioid use disorder using neurobehavioral markers of goals and habits. The key objectives are to: Track daily changes in motivational control during inpatient heroin addiction treatment with and without fentanyl use, to understand how goal-directed control evolves with abstinence. Use the...
This $403,542 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to profile projection-specific proteome associated with the incubation of oxycodone craving. The project will focus on the orbitofrontal cortex (OFC) to dorsal striatum (DS) projections, analyzing proteome changes in OFC neuronal somas (Aim 1) and OFC-DS projection-specific synaptoneurosomes in the DS (Aim 2) during the incubation of oxycodone...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on establishing OPRM1 exon 7-associated variants as novel therapeutic targets to mitigate adverse effects of clinically used mu opioids without altering analgesia in pain management. The total funding amount for this award is $2,902,673.00, with a project period from September 30, 2024 to May 31, 2029. The award was granted to Rutgers, The...
The National Institute on Drug Abuse (NIDA) awarded The Washington University a 3-year, $2,337,729 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to study the impact of prenatal opioid exposure on placental and fetal brain development. The project, titled "The Opioid in Pregnancy: Imaging of Oxygenation, Inflammation, and Development in Brain & Placenta" (OPIOID BPP), aims to define the longitudinal effects of prenatal opioid exposure on...

IMPACT OF OPIOID WITHDRAWAL ON SNL-TS DOPAMINE AND GLUTAMATE IN THREAT LEARNING - PROJECT SUMMARY THE OPIOID EPIDEMIC REMAINS A CRITICAL PUBLIC HEALTH CRISIS, MARKED BY HIGH RATES OF ADDICTION, OVERDOSE, AND MORTALITY. OPIOID ADDICTION IS A CHRONIC, RELAPSING DISORDER WITH WITHDRAWAL OFTEN TRIGGERING ANXIETY AND AVOIDANCE, LEADING TO SUBSEQUENT DRUG-SEEKING AND TAKING BEHAVIOR. THIS PROPOSAL AIMS TO INVESTIGATE THE NEURAL MECHANISMS UNDERLYING OPIOID WITHDRAWAL-INDUCED ANXIETY USING A COMBINATION OF BEHAVIORAL ANIMAL MODELS AND ADVANCED NEUROTECHNOLOGICAL TECHNIQUES. OUR EXPERIMENTAL APPROACH INVOLVES A MODEL IN WHICH MICE SELF- ADMINISTER ORAL OXYCODONE AND DISPLAY SOMATIC WITHDRAWAL SYMPTOMS WHEN OXYCODONE AVAILABILITY IS REMOVED. MY PRELIMINARY DATA SHOW THAT MICE WILL SELF-ADMINISTER ORAL OXYCODONE AND DISPLAY WITHDRAWAL SIGNS WHEN OXYCODONE AVAILABILITY IS REMOVED. FURTHER, EXPOSURE TO AN INNATELY THREATENING VISUAL LOOMING STIMULUS PROMPTS MICE TO ENGAGE IN DEFENSIVE BEHAVIORS, INCLUDING AVOIDANCE. HOWEVER, MY RECENT WORK INDICATES THAT REPEATED EXPOSURES TO THIS LOOMING STIMULUS LEADS TO DECREASED AVOIDANCE BEHAVIORS, DEMONSTRATING THAT THESE DEFENSIVE BEHAVIORS ARE ADAPTIVE. INTEGRATING THESE TWO MODELS, MY PRELIMINARY DATA SHOW THAT MICE UNDERGOING OPIOID FORCED ABSTINENCE EXHIBIT IMPAIRED ADAPTIVE DEFENSIVE RESPONSES, AS EVIDENCED BY THEIR PERSISTENT AVOIDANCE BEHAVIORS TOWARD THE LOOMING STIMULUS. THE MIDBRAIN-STRIATAL PATHWAY UTILIZES DOPAMINE AND GLUTAMATE FOR LEARNING OF REWARDING AND THREATENING STIMULI AND REINFORCES AVOIDANCE BEHAVIORS. THE MIDBRAIN REGION, SUBSTANTIAL NIGRA PARS LATERALIS (SNL) SENDS DOPAMINERGIC AND GLUTAMATERGIC PROJECTIONS TO THE TAIL OF THE STRIATUM (TS). PRELIMINARY DATA INDICATE THAT DOPAMINE AND GLUTAMATE RESPOND TO THREATENING STIMULI. ADDITIONALLY, DOPAMINE RELEASE IN THE TAIL OF THE STRIATUM (TS) INITIALLY RESPONDS TO THE VISUAL LOOMING STIMULUS AND ATTENUATES WITH REPEATED EXPOSURES. DURING OPIOID ABSTINENCE, DOPAMINE AND GLUTAMATE RESPONSE TO THREATENING STIMULI IS EXAGGERATED, THEREFORE, I HYPOTHESIZE IN OPIOID-ABSTINENCE DISRUPTS DOPAMINE AND GLUTAMATE FUNCTIONING IN THE TS, LEADING TO SUSTAINED AVOIDANCE BEHAVIOR TO THE LOOMING STIMULUS. A COMBINATION OF FIBER PHOTOMETRY, OPTOGENETICS, AND BEHAVIORAL ANALYSES OF OXYCODONE INTAKE AND DEFENSIVE BEHAVIORS WILL BE USED TO TARGET AND INVESTIGATE THE SNL-TS PATHWAY. IN AIM 1, WE WILL EVALUATE OPIOID WITHDRAWAL-INDUCED CHANGES IN DOPAMINE AND GLUTAMATE RELEASE FROM SNL NEURONS TO THE TS. IN AIM 2, WE WILL MANIPULATE DOPAMINE, GLUTAMATE, AND CO- TRANSMISSION OF DOPAMINE-GLUTAMATE FROM THE SNL TO THE TS DURING VLS PRESENTATIONS AND IDENTIFY CHANGES IN DEFENSIVE BEHAVIORS. THE DATA GENERATED FROM THIS PROJECT MAY IDENTIFY NOVEL MECHANISMS OF NEUROTRANSMITTER TRANSMISSIONS THAT MAY REDUCE OPIOID WITHDRAWAL-INDUCED ANXIETY.

Posted 4/14/25